抗高血糖药物标的遗传变异和炎症性肠病的风险:一个门德尔的随机化研究
Jiaxi Zhao1, Rong Chen2, Mengqi Luo3
1General Practice Ward / International Medical Center Ward General Practice Medical Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Diabetes & metabolic syndrome
|March 2, 2025
概括
抗高血糖药物点的遗传变异显示出与炎症性肠病 (IBD) 风险的潜在联系. 具体来说,SGLT2抑制剂标可能会增加克罗恩病的风险,而ABCC8和GLP-1RA标显示与IBD的关联.
科学领域:
- 药物基因组学 药物基因组学
- 胃肠病学 胃肠病学
- 遗传流行病学遗传流行病学
背景情况:
- 抗高血糖药物正在探索在炎症性肠病 (IBD) 中的潜在治疗作用.
- 影响药物点的遗传变异可能会影响IBD易感性.
研究的目的:
- 研究基因向抗高血糖药物中的遗传变异与发展IBD的风险之间的关联.
- 探索IBD风险与常见糖尿病药物相关的遗传基础.
主要方法:
- 利用英国生物银行 (n=344,182) 的汇总统计数据来获取HbA1c数据.
- 采用两个样本的门德尔随机化 (MR) 方法.
- 从英国炎症肠病遗传学联盟获得IBD统计数据.
主要成果:
- 增加SGLT2抑制剂标 (SLC5A2) 的表达,与较高的克罗恩病 (CD) 风险相关 (OR=1.97).
- 硫基尿素标 (ABCC8) 表达与IBD风险 (OR=1.11) 有积极联系.
- GLP-1RA目标 (GLP1R) 表达与IBD正相关 (OR=1.45).
- 通过IVW-MR, thiazolidinediones目标 (PPARG) 表达表明IBD和CD风险降低.
结论:
- 在SGLT2抑制剂标中的遗传变异可能会增加CD风险.
- ABCC8基因可能与IBD,CD和性结肠炎 (UC) 有关.
- GLP-1RA标表达的遗传变异可能与IBD发生产生正相关.
相关概念视频
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
293
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
293
01:29Inflammatory Bowel Disease IV: Pharmacological Management
88
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
88
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
151
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
151
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
142
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
142
01:24Glucagon-like Receptor Agonists
290
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
290
01:23Dipeptidyl Peptidase 4 Inhibitors
161
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
161